Table 1.
Baseline Demographic Characteristics
| Canagliflozin 300 mg (n=56) | Canagliflozin 100 mg (n=57) | Placebo (n=56) | Canagliflozin Total (n=113) | Total (N=169) | |
|---|---|---|---|---|---|
| Male, No. (%) | 31 (55.4) | 34 (59.6) | 33 (58.9) | 65 (57.5) | 98 (58.0) |
| Age, y | 58.3 (6.9) | 57.8 (8.7) | 59.6 (9.5) | 58.1 (7.8) | 58.6 (8.4) |
| Race, No. (%) | |||||
| White | 43 (76.8) | 45 (78.9) | 46 (82.1) | 88 (77.9) | 134 (79.3) |
| Black or African American | 12 (21.4) | 10 (17.5) | 9 (16.1) | 22 (19.5) | 31 (18.3) |
| Asian | 1 (1.8) | 1 (1.8) | 0 | 2 (1.8) | 2 (1.2) |
| Other | 0 | 1 (1.8) | 0 | 1 (0.9) | 1 (0.6) |
| Unknown | 0 | 0 | 1 (1.8) | 0 | 1 (0.6) |
| Ethnicity, No. (%) | |||||
| Hispanic or Latino/Latina | 26 (46.4) | 35 (61.4) | 33 (58.9) | 61 (54.0) | 94 (55.6) |
| Not Hispanic or Latino/Latina | 30 (53.6) | 22 (38.6) | 23 (41.1) | 52 (46.0) | 75 (44.4) |
| Body weight, kg | 96.1 (20.2) | 95.3 (22.2) | 91.7 (17.5) | 95.7 (21.2) | 94.3 (20.1) |
| BMI, kg/m² | 34.1 (6.8) | 33.0 (6.0) | 32.9 (5.7) | 33.6 (6.4) | 33.3 (6.2) |
| Glycated hemoglobin, % | 8.0 (0.8) | 8.1 (0.9) | 8.2 (0.9) | 8.0 (0.8) | 8.1 (0.9) |
| eGFR, mL/min/1.73 m2 | 85.6 (19.7) | 87.2 (20.3) | 87.9 (18.3) | 86.4 (19.9) | 86.9 (19.4) |
| FPG, mmol/L | 9.4 (2.0) | 9.7 (2.1) | 9.8 (2.4) | 9.5 (2.0) | 9.6 (2.2) |
| Seated SBP, mm Hg | 139.2 (8.8) | 138.5 (11.1) | 137.7 (8.6) | 138.9 (10.0) | 138.5 (9.6) |
| Seated DBP, mm Hg | 83.0 (8.2) | 82.4 (7.7) | 82.7 (8.6) | 82.7 (7.9) | 82.7 (8.1) |
| Mean 24‐h ABPM SBP, mm Hg | 139.6 (10.9) | 136.5 (11.5) | 136.7 (10.3) | 138.0 (11.3) | 137.6 (11.0) |
| Mean 24‐h ABPM DBP, mm Hg | 79.3 (7.9) | 78.0 (8.1) | 78.4 (7.3) | 78.7 (8.0) | 78.6 (8.0) |
Abbreviations: ABPM, ambulatory blood pressure monitoring; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; SBP, systolic blood pressure. Data are represented as mean (standard deviation) unless otherwise indicated.